186 related articles for article (PubMed ID: 10418960)
1. Partial inhibition of the P-glycoprotein-mediated transport of anthracyclines in viable resistant K562 cells after irradiation in the presence of a verapamil analogue.
Mankhetkorn S; Teodori E; Garnier-Suillerot A
Chem Biol Interact; 1999 Jul; 121(2):125-40. PubMed ID: 10418960
[TBL] [Abstract][Full Text] [Related]
2. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
Mankhetkorn S; Garnier-Suillerot A
Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
[TBL] [Abstract][Full Text] [Related]
3. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Mülder HS; Dekker H; Pinedo HM; Lankelma J
Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
[TBL] [Abstract][Full Text] [Related]
4. Study of P-glycoprotein functionality in living resistant K562 cells after photolabeling with a verapamil analogue.
Mankhetkorn S; Teodori E; Scapecchi S; Garnier-Suillerot A
Biochem Pharmacol; 1996 Jul; 52(2):213-7. PubMed ID: 8694845
[TBL] [Abstract][Full Text] [Related]
5. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells.
Nagasawa K; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jul; 19(7):971-6. PubMed ID: 8839972
[TBL] [Abstract][Full Text] [Related]
6. Comparison of uptake mechanisms for anthracyclines in human leukemic cells.
Karim H; Bogason A; Bhuiyan H; Fotoohi AK; Lafolie P; Vitols S
Curr Drug Deliv; 2013 Aug; 10(4):404-12. PubMed ID: 23062181
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
9. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.
Bennis S; Faure P; Chapey C; Hu YP; Fourche J; El Yamani J; Robert J
Anticancer Drugs; 1997 Jul; 8(6):610-7. PubMed ID: 9300576
[TBL] [Abstract][Full Text] [Related]
10. Relation between MDR1 mRNA levels, resistance factor, and the efficiency of P-glycoprotein-mediated efflux of pirarubicin in multidrug-resistant K562 sublines.
Meesungnoen J; Jay-Gerin JP; Mankhetkorn S
Can J Physiol Pharmacol; 2002 Nov; 80(11):1054-63. PubMed ID: 12489924
[TBL] [Abstract][Full Text] [Related]
11. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids.
Pereira E; Tarasiuk J; Garnier-Suillerot A
Chem Biol Interact; 1998 Jul; 114(1-2):61-76. PubMed ID: 9744556
[TBL] [Abstract][Full Text] [Related]
12. D-verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin.
Damiani D; Michieli M; Michelutti A; Melli C; Cerno M; Baccarani M
Anticancer Drugs; 1993 Apr; 4(2):173-80. PubMed ID: 8098233
[TBL] [Abstract][Full Text] [Related]
13. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
[TBL] [Abstract][Full Text] [Related]
14. The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.
den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
Leukemia; 1998 Jun; 12(6):912-20. PubMed ID: 9639420
[TBL] [Abstract][Full Text] [Related]
15. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
16. Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.
Benderra Z; Morjani H; Trussardi A; Manfait M
Int J Oncol; 1998 Mar; 12(3):711-5. PubMed ID: 9472114
[TBL] [Abstract][Full Text] [Related]
17. The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells.
Wielinga PR; Westerhoff HV; Lankelma J
Eur J Biochem; 2000 Feb; 267(3):649-57. PubMed ID: 10651800
[TBL] [Abstract][Full Text] [Related]
18. Saturable P-glycoprotein kinetics assayed by fluorescence studies of drug efflux from suspended human KB8-5 cells.
Ghauharali RI; Westerhoff HV; Dekker H; Lankelma J
Biochim Biophys Acta; 1996 Jan; 1278(2):213-22. PubMed ID: 8593279
[TBL] [Abstract][Full Text] [Related]
19. Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin.
Kang W; Weiss M
Pharm Res; 2001 Nov; 18(11):1535-41. PubMed ID: 11758760
[TBL] [Abstract][Full Text] [Related]
20. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.
Michieli M; Damiani D; Michelutti A; Candoni A; Masolini P; Scaggiante B; Quadrifoglio F; Baccarani M
Haematologica; 1994; 79(6):500-7. PubMed ID: 7896208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]